BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Phenomenex, Inc. Release: New 5-Micron C8 Kinetex Core-Shell Media Addresses Difficult-to-Resolve Compounds


6/4/2013 11:26:48 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Torrance, CA (June 4, 2013) - Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces the Kinetex C8 5-micron core-shell HPLC column. The widely used C8 phase delivers optimum retention for the analysis of hydrophobic and "sticky" compounds. In combination with Kinetex Core-Shell Technology, this phase gives analysts an excellent high-performance reversed phase alternative for HPLC methods. As with the existing Kinetex 5-micron C18 and XB-C18 phases, the new 5-micron C8 core-shell column can be easily substituted into methods that meet United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.) requirements. Specifically the Kinetex 5-micron C8 meets USP specifications for Classification Code L7, enabling laboratories using 5-micron L7 columns to realize the performance benefits of Kinetex Core-Shell Technology without adjusting their USP methodology.

The largest diameter particle in the family, Kinetex 5-micron core-shell media delivers better performance than 3 and 5-micron fully porous offerings, with no increase in backpressure. In fact, the new 5-micron media provides 90 percent higher average efficiencies compared to the same size fully porous columns with little to no method development. Kinetex 5-micron C8 columns are fully scalable to or from the 1.7- and 2.6-micron particles, enabling easy method transferability.

"This new 5-micron phase expands our ever-growing Kinetex product line, which meets customers' needs from UHPLC to HPLC to small-scale preparative purification," comments Simon Lomas, brand manager for Phenomenex. "Kinetex Core-Shell Technology delivers huge performance advantages over conventional, fully porous media, such as sharper peaks, reduced run times, and more smiles in the lab."

Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being.

For more information on Phenomenex, visit www.phenomenex.com or follow the company on Twitter @Phenomenex.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES